Related Experiment Video

Updated: May 23, 2026

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
08:24

Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation

Published on: May 22, 2017

Novel HDL-based therapeutic agents

Tisha R Joy1

  • 1Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada N6A 5K8. tisjoy@hotmail.com

Pharmacology & Therapeutics
|April 3, 2012
PubMed

Insights

New therapies aim to boost high-density lipoprotein cholesterol (HDL-C) or improve its function to further reduce cardiovascular disease risk, beyond lowering LDL-C. This review covers novel agents targeting HDL-C.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) risk by 25-30%, yet residual risk persists.
  • Low high-density lipoprotein cholesterol (HDL-C) levels are linked to increased CVD risk.
  • Novel therapeutic strategies are needed to address residual CVD risk by targeting HDL-C.

Purpose of the Study:

  • To review emerging therapeutic agents designed to increase HDL-C levels or enhance HDL functionality.
  • To provide an overview of the mechanisms of action, pharmacokinetics, and efficacy/safety data for these novel therapies.

Main Methods:

  • Review of current literature on novel HDL-C-targeting therapies.
  • Analysis of therapeutic classes including cholesteryl ester transfer protein (CETP) inhibitors, apolipoprotein A-I (apoA-I) mimetics, RVX-208, and apoA-I based infusion therapies.

Main Results:

  • Discussion of CETP inhibitors, apoA-I mimetics, RVX-208, and apoA-I infusion therapies.
  • Presentation of mechanism of action, pharmacokinetic profiles, and clinical trial data (efficacy and safety) for each agent class.

Conclusions:

  • Emerging therapies targeting HDL-C offer potential for further cardiovascular risk reduction.
  • Further research and clinical validation are necessary to establish the role of these agents in managing cardiovascular disease.

More Related Videos

Formulation and Characterization of Bioactive Agent Containing Nanodisks07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...